INTS
Intensity Therapeutics, Inc. Common stockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$13.13M
P/E Ratio
—
EPS
$-8.56
Beta
4.23
52W High
$43.50
52W Low
$4.63
50-Day MA
$6.23
200-Day MA
$8.23
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc. is an innovative biotechnology firm dedicated to transforming cancer treatment through its advanced drug delivery systems. The company specializes in enhancing the effectiveness of immuno-oncology therapies while reducing systemic side effects, effectively addressing significant unmet needs in oncology. With a strong emphasis on cutting-edge research and development, Intensity Therapeutics is strategically positioned to spearhead advancements in targeted therapies, aiming to bolster the body's immune response against cancer and ultimately improve patient outcomes.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -156.90% |
| Return on Assets | -79.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.70 |
| Price-to-Book | 1.12 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.72 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $2.54M |
| Float | $2.32M |
| % Insiders | 4.85% |
| % Institutions | 8.08% |
Historical Volatility
HV 10-Day
17.06%
HV 20-Day
32.73%
HV 30-Day
48.76%
HV 60-Day
110.79%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($41.50 target)
6
BuyData last updated: 4/29/2026